Breaking news
Harbinger Health Raises $140 Million in Series B Financing
The firm said the funds will enable completion of clinical validation of its first blood-based cancer screening product ahead of an anticipated 2025 launch.
BioMérieux's BioFire Defense Secures $18.8M US DoD Contract for Infectious Disease Testing
The order-dependent contract is for maintenance and support of a version of the BioFire FilmArray 2.0 molecular diagnostic instrument through January 2029.
US Wins $370M Judgment in Lab Fraud Case
A US district court awarded the judgment against a Kentucky lab owner accused of billing Medicare for molecular testing not ordered by a healthcare provider.
Biora Therapeutics Settles Claims of Misleading Genetic Testing Advertisements
The company, formerly known as Progenity, was accused of violating consumer protection laws by making misleading claims about the costs of its genetic testing services.
Thermo Fisher Scientific Gets FDA Clearance for Neuroendocrine Cancer Assay
The BRAHMS CgA II KRYPTOR immunoassay is for use to track tumor progression for neuroendocrine cancer patients by measuring CgA concentration in serum.
Evvy Closes $14M Series A for Vaginal Microbiome Testing, Launches Add-on STI Screen
The New York-based firm will use the funds to scale access to its testing, discover new vaginal health biomarkers, and validate outcomes of its service.
MDxHealth, University of Oxford to Assess Prostate Test for Predicting Localized Treatment Outcomes
Investigators will work with the company to study the correlation between test results and patient outcomes after localized treatment in a UK cohort.
Biocartis Restructures Balance Sheet as H1 2023 Revenues Rise 12 Percent
The company said that its secured creditors have recapitalized its operating subsidiaries and restructured its balance sheet to reduce its debt burden by €132 million.
SEC Concludes CareDx Investigation, Recommends No Enforcement Action
The SEC informed CareDx in a letter that it had concluded an investigation into the company's accounting and public reporting practices.
Streck Quality Controls for DiaSorin's Luminex Sepsis Tests Receive FDA Clearance
The quality controls are designed to verify the performance of the Luminex Verigene Blood Culture Gram-Positive and Gram-Negative tests.